These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25144624)

  • 1. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.
    Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ;
    Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
    Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
    Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
    Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
    PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
    Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG
    Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
    Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
    Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.
    Kwee S; Song MA; Cheng I; Loo L; Tiirikainen M
    Clin Transl Sci; 2012 Feb; 5(1):65-70. PubMed ID: 22376260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy.
    Jentzmik F; Krause H; Reichelt U; Schrader AJ; Schrader M; Baumunk D; Cash H; Miller K; Schostak M
    World J Urol; 2012 Aug; 30(4):541-6. PubMed ID: 21947551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    Int J Urol; 2010 May; 17(5):466-75. PubMed ID: 20337729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
    Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
    Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
    Wu T; Giovannucci E; Welge J; Mallick P; Tang WY; Ho SM
    Br J Cancer; 2011 Jun; 105(1):65-73. PubMed ID: 21654682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
    Rouprêt M; Hupertan V; Catto JW; Yates DR; Rehman I; Proctor LM; Phillips J; Meuth M; Cussenot O; Hamdy FC
    Int J Cancer; 2008 Feb; 122(4):952-6. PubMed ID: 17960617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis.
    Dumache R; Puiu M; Motoc M; Vernic C; Dumitrascu V
    Clin Lab; 2014; 60(5):847-52. PubMed ID: 24839830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
    Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
    Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.
    Maldonado L; Brait M; Loyo M; Sullenberger L; Wang K; Peskoe SB; Rosenbaum E; Howard R; Toubaji A; Albadine R; Netto GJ; Hoque MO; Platz EA; Sidransky D
    J Urol; 2014 Nov; 192(5):1542-8. PubMed ID: 24769028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study.
    He L; Gao L; Shi Z; Li Y; Zhu L; Li S; Zhang P; Zheng G; Ren Q; Li Y; Hu B; Feng F
    PLoS One; 2015; 10(3):e0119481. PubMed ID: 25798582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between lifestyle factors and CpG island methylation in a cancer-free population.
    Brait M; Ford JG; Papaiahgari S; Garza MA; Lee JI; Loyo M; Maldonado L; Begum S; McCaffrey L; Howerton M; Sidransky D; Emerson MR; Ahmed S; Williams CD; Hoque MO
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2984-91. PubMed ID: 19861513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma.
    Jain S; Chen S; Chang KC; Lin YJ; Hu CT; Boldbaatar B; Hamilton JP; Lin SY; Chang TT; Chen SH; Song W; Meltzer SJ; Block TM; Su YH
    PLoS One; 2012; 7(4):e35789. PubMed ID: 22536438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.
    Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; PRIMe Consortium ; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG
    Int J Cancer; 2017 Nov; 141(10):2112-2120. PubMed ID: 28741687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.